These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15916446)

  • 21. Short-course treatment of community-acquired pneumonia.
    Mandell LA; File TM
    Clin Infect Dis; 2003 Sep; 37(6):761-3. PubMed ID: 12955635
    [No Abstract]   [Full Text] [Related]  

  • 22. Children with pneumonia: how do they present and how are they managed?
    Clark JE; Hammal D; Spencer D; Hampton F
    Arch Dis Child; 2007 May; 92(5):394-8. PubMed ID: 17261579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community-acquired pneumonia in infants and children.
    Ostapchuk M; Roberts DM; Haddy R
    Am Fam Physician; 2004 Sep; 70(5):899-908. PubMed ID: 15368729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are new antibiotics better than beta-lactams for non-critical inpatients with community-acquired pneumonia?
    Reyes B T; Ortega G M; Saldías P F
    Medwave; 2016 Aug; 16 Suppl 3():e6499. PubMed ID: 27512983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventilator-associated pneumonia: gearing towards shorter-course therapy.
    Chua Tde J; File TM
    Curr Opin Infect Dis; 2006 Apr; 19(2):185-8. PubMed ID: 16514344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.
    Galli L; Montagnani C; Chiappini E; de Martino M
    Acta Paediatr; 2013 Dec; 102(465):25-33. PubMed ID: 24330270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community-acquired pneumonia in children: what to do when there is no response to standard empirical treatment?
    Shanthikumar S; Clifford A; Massie J; Cole T; Steer A; Marks M; Gwee A
    Thorax; 2016 Oct; 71(10):957-9. PubMed ID: 27503231
    [No Abstract]   [Full Text] [Related]  

  • 29. Monotherapy in severe community-acquired pneumonia: is it worthy?
    Torres A
    Chest; 2005 Jul; 128(1):10-3. PubMed ID: 16002907
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of 3-day versus 5-day antibiotic therapy for clinically diagnosed nonsevere pneumonia in children from developing countries.
    Sutijono D; Hom J; Zehtabchi S
    Eur J Emerg Med; 2011 Oct; 18(5):244-50. PubMed ID: 21394031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
    Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
    Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging problems in the treatment of pediatric community-acquired pneumonia.
    Principi N; Esposito S
    Expert Rev Respir Med; 2018 Jul; 12(7):595-603. PubMed ID: 29883232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Trials; 2015 Aug; 16():355. PubMed ID: 26272324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reducing the duration of antibiotic therapy in acute community-acquired pneumonia].
    Groupe Entretiens du Club de réflexion sur l'infection respiratoire
    Rev Pneumol Clin; 2008 Feb; 64(1):3-7. PubMed ID: 18603172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic stewardship in community-acquired pneumonia.
    Viasus D; Vecino-Moreno M; De La Hoz JM; Carratalà J
    Expert Rev Anti Infect Ther; 2017 Apr; 15(4):351-359. PubMed ID: 28002979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Community-acquired pneumonia in children: issues in optimizing antibacterial treatment.
    Korppi M
    Paediatr Drugs; 2003; 5(12):821-32. PubMed ID: 14658923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The use of stepwise antibacterial therapy of community-acquired pneumonia].
    Iashchenko AV; Sinopal'nikov AI
    Klin Med (Mosk); 2014; 92(6):53-6. PubMed ID: 25799831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines-concordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation.
    Sakamoto Y; Yamauchi Y; Yasunaga H; Takeshima H; Hasegawa W; Jo T; Matsui H; Fushimi K; Nagase T
    Respir Investig; 2017 Jan; 55(1):39-44. PubMed ID: 28012492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children.
    Muszynski JA; Knatz NL; Sargel CL; Fernandez SA; Marquardt DJ; Hall MW
    Pediatr Infect Dis J; 2011 Apr; 30(4):295-301. PubMed ID: 21030885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial community-acquired pneumonia in children: changes in causative agents.
    Korppi M; Heiskanen-Kosma T
    Monaldi Arch Chest Dis; 2001 Apr; 56(2):132-6. PubMed ID: 11499302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.